Cat. No. ARG43831
The Eif2a Knockout Vero Cell Line is a CRISPR/Cas9-edited knockout cell model from Vero kidney epithelial cells (Chlorocebus aethiops). Disrupting EIF2A, which recruits initiator Met-tRNA to the 40S subunit with eIF3 and eIF5B for IRES-mediated translation under stress, it lies downstream of mTORC1 and regulates c-MYC and XIAP. Ideal for exploring stress-induced translation, viral IRES exploitation, and antiviral screening, the line supports polysome profiling, IRES reporters, and stress granule analysis. It provides a primate model for non-canonical translation studies.
| Host Cell | Vero |
| Sex of Donor | Female |
| Age | Adult |
| Derived From Site | Epithelium, Kidney |
| Gene Name | EIF2A |
| Gene Identifier | NCBI Gene ID 103241482 |
| Morphology | Epithelial-like |
| Growth Mode | Adherent |
| Storage | Liquid nitrogen (LN2) |
| Temperature | 37°C |
| Atmosphere | 5% CO₂ |
| Sterility testing | The bacterial, yeast, and fungi are not detected in these cells by daily monitor. |
| Mycoplasma testing | Negative for mycoplasma through PCR analysis |
Intended Use: This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer: Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use.
This product is provided "AS IS". For Research Use Only. Not for human or animal therapeutic use.
The Eif2a Knockout Vero Cell Line is a CRISPR/Cas9-edited knockout cell line that disrupts the Eif2a gene in Vero kidney epithelial cells (Chlorocebus aethiops). This loss-of-function model eliminates EIF2A-dependent non-canonical translation initiation, providing a clean system to dissect alternative translation pathways. The stable cell line is generated using robust gene-editing technology and is supplied ready for immediate use in stress-related translational research.
Vero cells are an immortalized, non-tumorigenic epithelial line derived from African green monkey kidney. Widely utilized in virology and vaccine production, they are permissive to many human viruses and lack interferon production, simplifying host?Cpathogen studies. The Eif2a knockout variant retains parental cell growth characteristics while permitting focused investigation of EIF2A-mediated functions in a defined primate cellular context.
EIF2A facilitates codon-independent delivery of initiator methionyl-tRNA to the 40S ribosomal subunit, a critical step in IRES-mediated translation initiation during stress when canonical eIF2 activity is compromised by eIF2?? phosphorylation. It physically associates with the 40S subunit, the eIF3 complex, eIF5B, PABP, and IRES trans-acting factors, and is activated by upstream signals including mTORC1, hypoxia, amino acid deprivation, and viral infection. EIF2A drives translation of downstream targets such as the proto-oncogene c-MYC and the apoptosis inhibitor XIAP, and contributes to the integrated stress response via PERK/EIF2AK3 and GCN2/EIF2AK4 kinases and the transcription factor ATF4. Additionally, it influences stress granule assembly dynamics.
In the Vero cell context, knockout of EIF2A dismantles a pathway commonly exploited by viruses possessing IRES elements??such as filoviruses and flaviviruses??to maintain protein production when host translation is shut off. This makes the knockout line a powerful substrate for antiviral screens targeting IRES-dependent translation. Moreover, Vero cells?? flat epithelial architecture and robust response to stress agonists enable high-resolution imaging of stress granules and ribosomal structures, facilitating detailed mechanistic studies of translation reprogramming and stress adaptation.
Key applications include mechanistic dissection of stress-induced translational control, high-throughput screening for IRES-targeted antiviral compounds, and modeling translation dysregulation in cancer and neurodegeneration. The line supports a broad array of assays: western blotting for phospho-eIF2?? and ATF4, polysome profiling, dual-luciferase IRES reporter systems, puromycin incorporation (SUnSET), co-immunoprecipitation with ribosomal proteins, immunofluorescence for stress granule markers such as G3BP1, viral plaque assays, and RNA-seq of polysome-associated mRNAs. For further details or to request custom validation data, please contact Ascent Research.